产品名称 | Seraseq® Compromised FFPE Tumor DNA RM (SeraCare) |
---|---|
目录号 | 0710-1492 |
别名 | N/A |
外观 | N/A |
分子量 | N/A |
CAS | N/A |
溶解度 | N/A |
存储条件 | N/A |
保存时间 | N/A |
备注1 | N/A |
备注2 | N/A |
目录号 | 规格 | 价格 | 库存状态 | |
0710-1492 | 1 x 10 µm | 咨询客服 | 咨询客服 |
品名:Seraseq® Compromised FFPE Tumor DNA RM
货号:0710-1492
品牌:SeraCare
Product Specifications - Compromised FFPE Tumor DNA RM
# of genes 17
Size 10 µm
Format FFPE
DNA Yield >100 ng*
*QIAamp FFPE Tissue DNA Kit
Details
Comprehensive genomic profiling (CGP) is an important part of an integrated clinical management of cancer patients,
where cancer patients harboring variants/biomarkers of clinical utility are determined by highly multiplexed targeted
NGS assay testing. Precise analysis of these patient samples requires high quality sample-to-result assay workflow
controls to guide and validate the accurate identification of these actionable variants. LGC SeraCare has developed a
highly multiplexed Compromised FFPE Tumor DNA reference material imbibing “patient-like” characteristics to
support end-to-end NGS workflows performed by clinical labs in the analysis of cancer patient samples. This product
consists of 17 genes and 34 variants, incorporating all variant types – SNVs, INDELs, CNVs, and SVs. These variants
were precisely quantitated by digital PCR and targeted NGS against a single well-characterized genomic background
(GM24385).
Highly multiplexed FFPE Tumor DNA reference material
Contains 34 variants in 17 genes
All variant types – SNVs (18), INDELs (10), CNVs (3) and SVs (3)
For use in sample-to-result NGS workflows to analyze for mutation-positive variants in patient samples
Manufactured in GMP-compliant ISO 13485 certified facility
维百奥生物代理SeraCare对照及参比物质。
维百奥(北京)生物科技有限公司,自2018年与SeraCare(现隶属于LGC Clinical Diagnostics)合作以来,长期为中国客户
提供包括SeraSeq系列参比物质,领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质,可以用于任何
研发阶段,以确保临床基因组学检测结果的准确性。
SeraCare参比物质涵盖的范围:
1)Next Generation Sequencing
2)Sanger Sequencing
3)Real-time PCR and digital PCR (dPCR)
4)Microarray
主要特点
1)Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs,
and RNA fusions
2)Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs
3)Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA
in plasma, and FFPE
4)Manufactured in cGMP-compliant, ISO 13485-certified facilities
5)Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers